Press Release: atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Saved in:
Bibliographic Details
Published inDow Jones Institutional News
Format Newsletter
LanguageEnglish
Published New York Dow Jones & Company Inc 13.04.2023
Subjects
Capital expenditures
Clinical trials
Epidemics
Intellectual property
Ketamine
Life sciences
Mental depression
Mental disorders
Mental health care
Neurosciences
Pandemics
Product development
R&D
Regulatory approval
Research & development
Safe harbor
Success
Therapists
Online AccessGet full text

Cover

More Information
Description not available.